Drug makers failed to complete one-third of required studies after drugs were approved by federal regulators, a report released Monday concluded. The finding from the Government Accountability Office is the latest knock against the enforcement power of federal agencies that oversee drug and medical device makers. Some studies had been pending for five to eight years, the report noted.